46 results about "Acute hepatic failure" patented technology

The invention provides an application of exosome to preparing of acute-hepatic-failure treating medicine. The exosome is an exosome secreted through personal-menstrual-blood mesenchymal stem cells. The invention further provides a medicine composition, wherein the medicine composition comprises the exosome secreted through the personal-menstrual-blood mesenchymal stem cells and carriers acceptable in pharmacy. According to the medicine composition in the technical scheme, the survival time of an acute-hepatic-failure animal model can be prolonged, the bleeding rate and the necrotic rate of the livers can be decreased, and secreting of inflammatory factors through liver cells can be promoted, so that acute hepatic failure is effectively treated, and prognosis of an acute-hepatic-failure patient is improved accordingly.

The invention provides a combining reagent for preparing a bioartificial liver stent. The reagent comprises perfusate 1, perfusate 2, perfusate 3, perfusate 4, eluent 1 and eluent 2, wherein the perfusate is alkalescent hypotonic solution or pure water; the perfusate 2 is a group of ionic detergent aqueous solutions with gradient concentration; the perfusate 3 is aqueous electrolyte solution; theperfusate 4 is anticoagulant factor aqueous solution; the eluent 1 is distilled water; and the eluent 2 is non-ionic detergent aqueous solution. The invention also provides a method for preparing an implantable bioartificial liver by using the combining reagent, and the implantable bioartificial liver prepared by using the method. The bioartificial liver stent prepared by using the combining reagent is decellularized completely; and the structure of an extracellular matrix is kept complete. The bioartificial liver can accommodate a large number of cells and provide adequate blood supply, so that the survival time of a rate with an acute hepatic failure is prolonged obviously; and a liver function is improved obviously. Therefore, the bioartificial liver has an extremely good clinical application prospect.

The invention discloses an in vitro construction method of liver organs and applications. Mouse hepatocytes are extracted to induce to construct liver organs; the forms of the liver organs are observed under a microscope; and immunofluorescence and PCR identification are performed on dryness and epithelial cell properties. An acute hepatic failure mouse model after 70% hepatectomy is established;the liver functions on the first, fourth and seventh day after operation are evaluated after the liver organs are transplanted; liver-to-body ratio is compared; and the treatment effects of the liverorgans on acute hepatic failure are verified through HE staining and immunohistochemistry. Inflammations such as HE staining and ki-67 staining and proliferation indexes show that proliferation can beobviously enhanced after the liver organs are transplanted. The liver organs have strong dryness and proliferation functions; the liver functions of acute hepatic failure mice after 70% hepatectomy can be effectively relieved, and the liver-to-body ratio can be increased; and liver regeneration and repair of acute hepatic failure after 70% hepatectomy can be promoted by relieving inflammatory infiltration of livers.

The invention relates to the biomedical field, and particularly relates to application of dihydromyricetin in preparation of a liver treatment and regeneration promotion medicine. Dihydromyricetin shows relatively high oxidation resistance and characteristic on promoting cell growth as a flavonoid compound. The test shows that dihydromyricetin can effectively relieve liver tissue necrosis caused by acute hepatic failure and can promote hepatocyte proliferation, so as to obviously raise the survival rate of a model mouse suffering from acute hepatic failure; dihydromyricetin also can obviously improve the activity of superoxide dismutase in tissue and serum, increase the content of serum protein, and lower down the levels of glutamic oxalacetic transaminase, glutamic-pyruvic transaminase and tumor necrosis factor alpha.

The invention discloses application of peripheral blood mononuclear cell activation inhibitors to preparing a medicine for treating and / or preventing acute hepatic failure, and further provides the medicine for treating and / or preventing the acute hepatic failure. The medicine is a preparation, the peripheral blood mononuclear cell activation inhibitors are used as active substances for the preparation, and pharmacologically acceptable excipients or auxiliary components are added into the peripheral blood mononuclear cell activation inhibitors to prepare the preparation. The application and the medicine have the advantages that the fact that activation of mononuclear cells can be effectively inhibited is proved, accordingly, acute hepatic injury can be effectively treated and prevented, a novel option can be provided for clinically treating the acute hepatic injury, and the medicine has an excellent application prospect.

The invention provides an exosome from adipose-derived stem cells and a preparation method thereof. The exosome from the adipose-derived stem cells can be used for treating an acute hepatic failure, liver fibrosis, liver cirrhosis and other liver diseases. The exosome from the adipose-derived stem cells can remarkably increase the survival rate of a patient with the acute hepatic failure and evencan realize the 100% survival rate of the patient with the acute hepatic failure under high concentration.

The invention relates to the technical field of biomedical engineering. Liver transplantation is the only effective means that can be employed for treating liver diseases in late stage at present and is greatly limited in clinic use due to lack of liver sources. Hepatic stem cells have a self-updating capacity and a bidirectional differentiation capacity of differentiating into hepatocytes and cholangiocytes and therefore can provide an infinite number of donor cells for hepatocyte transplantation treatment in theory. The method for the transdifferentiation of fibroblasts into hepatic stem cells, which is provided by the invention, is to reprogram fibroblasts into hepatic stem cells which have the unique self-updating and bidirectional differentiation capacities of hepatic stem cells by using three transcription factors, namely c-Jun, Foxa2 and Hnf1beta. The inducible hepatic stem cells prepared by the method can be used as ideal cell sources for cell treatment of acute hepatic failure and liver diseases in medium and late stages, can be used as seed cells for medicine screening and tissue engineering livers and can provide an ideal research platform for researching cell biological characteristics of hepatic stem cells, liver development and the like.

The invention discloses application and a method of a stem cell population (NG2+HSC (hematopoietic stem cell)) of hepatogenous expression NG2 (neuron-glial antigen 2) as seed cells in in-vitro 3D (three-dimensional) culture and reconstruction of an artificial liver. The method includes: injecting the NG2+HSC into a decellularized liver natural biological scaffold, adding a medium allowing the NG2+HSC to be reconstructed into the artificial liver, and simulating a microenvironment for the development and formation of in-vivo liver tissues to perform in-vitro 3D culture and reconstruction of the liver. The application and the method have the advantages that the method is simple, the cost is low, the culture time is short, the complete liver outline can form in 21 days, the artificial liver cultured has a hepatic lobule structure similar to normal liver tissues, hepatic functional proteins increase over culture time, the artificial liver has the function of repairing the hardened liver and acute hepatic failure and has the function of functional recovery, and the artificial liver can serve as a liver implant and is of great significance to clinic treatment of end-stage liver diseases.

The invention discloses application of adenosine and derivatives thereof in prevention and treatment of medicament-induced liver injury, relating to application of adenosine and derivatives thereof such as adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in protection of acetaminophen-induced liver injury. A mouse model adopted in the application is an acetaminophen-induced mouse acute hepatic failure model, the dosage of the adenosine or derivatives thereof is 0.1 to 5mmol / kg, and the adenosine and derivatives thereof can reduce the activities of aspartate aminotransferase (AST) and alanine transaminase (ALT) in the medicament-induced liver injury, reduce the substantial cell necrosis area and improve the glutathione level so as to prevent and treat the acetaminophen-induced liver injury caused by liver toxic medicaments. Animal experiments prove that the adenosine and derivatives thereof have a significant effect on preventing and treating the medicament-induced liver injury, so the adenosine and derivatives thereof can be used for the preventing and treating processes of the medicament-induced liver injury, and a new method and means are provided for clinically treating the medicament-induced liver injury.

The invention discloses a pharmaceutical composition of acetolide acetate and its medical application. The pharmaceutical composition of acetolide acetate provided by the invention contains acetolide acetate and a kind of The obtained natural product compound (I) with a novel structure, alanorelin acetate and compound (I) acting alone can reduce the content of serum transaminase, bilirubin and urea nitrogen in animals with liver damage, alleviate jaundice and renal dysfunction, And can reduce plasma endotoxin content; when alanorelin acetate and compound (I) act in combination, the pharmacological effect is more obvious, can be developed into the medicine for the treatment of acute liver failure, has outstanding substantive characteristics compared with the prior art and significant progress.

The invention discloses application of FC-99 shown as a formula (I) in preparing drug for preventing or treating acute hepatic failure, particularly relates to application of FC-99 in inducing expression of Let-7a (microRNA Let-7A) to inhibit occurrence and development of hepatic failure so as to prevent or treat the hepatic failure and belongs to the field of biomedicine. By building an acute hepatic failure mouse animal model induced by D-aminogalactose combined with lipopolysaccharide and intervening fulminant hepatic failure through FC-99, a result shows that FC-99 can obviously lower transaminase, inhibit inflammation factor release, reduce hepatic cell apoptosis and maintain liver microscopic structure stable and can remarkably lower death rate of mice with acute hepatic failure; bioinformatic analysis and molecular biological detection find that FC-99 is realized by inducing high expression of Let-7a and inhibiting gene expression of IL-6, IRF4, CD86 and SOCS1 in a targeted manner. Therefore, research results show that the compound FC-99 can be applied in preparing drug for preventing or treating acute hepatic failure. In the above application, dosage range for injection andoral administration is 0.01-1000mg per day, and the range can be deviated according to illness degree or dosage form difference.

The invention discloses application of berberine hydrochloride shown as a formula (I) in preparation of a medicine used for preventing and / or treating acute hepatic failure and belongs to the field of biological medicine. According to the invention, the prevention and treatment effects of berberine hydrochloride to acute hepatic failure are inspected by building a D-galactosamine and LPS (lipopolysaccharide)-induced acute hepatic failure mouse animal model; results of experimental analysis in biology, pharmacology and molecular biology show that the effects of obviously reducing transaminase, inhibiting oxidative stress injury and inhibiting release of inflammatory factors can be realized by virtue of administration of berberine hydrochloride, and the death rate of acute hepatic failure mice can be obviously reduced, so that research results of the invention show that berberine hydrochloride can be applied to preparation of the medicine used for preventing and / or treating the acute hepatic failure. The formula (I) is described in the specification.

The invention discloses a pharmaceutical use of argininyl fructosy glucose, and belongs to the field of research and development of pharmaceutical products. The pharmaceutical use refers to application of the argininyl fructosy glucose, as an active ingredient, in preparation of drugs for treating or preventing acute hepatic failure. The acute hepatic failure is oxidative stress injury caused by the combination of lipopolysaccharide and D-galactosamine, liver cells are protected from injuries, and apoptosis caused by LPS / D-GalN is reduced. The purity of the argininyl fructosy glucose is 80-99.99%. The argininyl fructosy glucose is applied to prevention or treatment of the acute hepatic failure for the first time, so that a new raw material is provided for the preparation of the drugs for the acute hepatic failure, and a new method is also provided for the prevention and treatment of the acute liver failure.

The invention provides an application of CST1 in prevention and / or treatment of liver immune disorder diseases. Specifically, the invention provides an application of a CST1 gene, or a protein thereof or an accelerant thereof, the CST1 gene, or the protein thereof or the accelerant thereof is used for preparing a composition or a preparation, and the composition or the preparation is used for preventing and / or treating liver immune disorder diseases. The invention also accidentally finds that the CST1 protein and the CST1 overexpression-based cell therapy have great potential for the treatment of acute hepatic failure.

Methods, formulations and kits for treating and / or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent which replenishes, or decreases a loss of, functional glutathione in the individual, and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.

The invention discloses an early diagnosis index for chemical-induced and drug-induced acute liver failure and a diagnosis index, namely a fibroblast growth factor 21 (hereinafter referred to as FGF21), for alcoholic fatty liver diseases. The early diagnosis index and the diagnosis index have the advantages that an index with early diagnosis functions is urgently required as acute liver failure is short in disease course; the diagnosis index FGF21 has a characteristic that the diagnosis index FGF21 is sensitive as compared with existing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminease, the recombinant human FGF21 can protect liver tissues against being injured by acetaminophen, and accordingly the early diagnosis index and the diagnosis index have excellent clinical application value.

With the present invention, liver cell function research of a human fetal liver cell line L-02 is performed, and the human fetal liver cell line L-02 is adopted in liver cell transplantation. The research results show that: the L-02 cells have good liver cell functions, can express a plurality of liver cell specificity factors, wherein the liver cell specificity factors comprise albumin, bilirubin glucuronosyltransferase, blood coagulation factors, transaminase and the like. 90% hepatectomy-induced acute liver failure (ALF) rat model experiment results show that: the survival time of the ALF rats can be effectively prolonged with the L-02 cells, the tumorigenesis risk does not exist, the L-02 cells is expected to be the good cell source for liver cell transplantation, bioartificial liver, medical researches related to the liver cell functions, and the like, and is applicable for treatment of the ALF, liver cell function researches, and other medical fields.

The invention relates to an adult human hepatogenic stem cell line HN, a preparation method thereof and an application. The human hepatogenic stem cell line is collected at the China General Microbiological Culture Collection Center, the collection address is No. 3, first yard, Beichen West Road, Chaoyang District, Beijing, the collection date is May 15, 2017, and the collection number is CGMCC No. 13844. The human hepatogenic stem cell line is used for in vitro and vivo directional induction of liver cells and hepatic duct epithelial cells, preparation of biological artificial livers, resistance of acute hepatic failure, chronic hepatic failure and alcoholic fatty livers, inhibition of liver fibrosis and anti-tumor effects. The cells have the biological characteristics that the cells have typical epithelial cell morphology and strong multiplication capacity, grow to achieve contact inhibition and density inhibition, bidirectionally express liver cell specific marker albumin, cytokeratin 8 and biliary epithelial cell specific marker cytokeratin 7 and 9, have various functions of the liver cells, have multi-directional differentiation potential and avoid tumorigenicity.

The invention provides a preparation method of hepatocyte-like cells prepared from humanized adipose-derived stem cells and an obtained hepatocyte-like cell population. The method includes the steps that in a specific induced differentiation step, a specific cell factor combination is used, and in this way, the highly-mature hepatocyte-like cells are obtained from the humanized adipose-derived stem cells and then used for treating an acute hepatic failure.

The invention provides a combining reagent for preparing a bioartificial liver stent. The reagent comprises perfusate 1, perfusate 2, perfusate 3, perfusate 4, eluent 1 and eluent 2, wherein the perfusate is alkalescent hypotonic solution or pure water; the perfusate 2 is a group of ionic detergent aqueous solutions with gradient concentration; the perfusate 3 is aqueous electrolyte solution; theperfusate 4 is anticoagulant factor aqueous solution; the eluent 1 is distilled water; and the eluent 2 is non-ionic detergent aqueous solution. The invention also provides a method for preparing an implantable bioartificial liver by using the combining reagent, and the implantable bioartificial liver prepared by using the method. The bioartificial liver stent prepared by using the combining reagent is decellularized completely; and the structure of an extracellular matrix is kept complete. The bioartificial liver can accommodate a large number of cells and provide adequate blood supply, so that the survival time of a rate with an acute hepatic failure is prolonged obviously; and a liver function is improved obviously. Therefore, the bioartificial liver has an extremely good clinical application prospect.

The invention discloses an anti-hepatic fibrosis traditional Chinese medicine compound composition and application thereof The traditional Chinese medicine compound composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-30 parts of astragalus membranaceus, 10-30 parts of radix pseudostellariae, 5-15 parts of angelica sinensis, 5-15 parts of glossy privet fruit, 5-15 parts of poria cocos, 10-30 parts of roasted rhizoma atractylodis macrocephalae, 5-15 parts of pericarpium citri reticulatae, 5-15 parts of wine-processed scutellaria baicalensis and 3-10 parts of honey-fried licorice root. According to the pathogenesis of hepatic fibrosis, a syndrome differentiation and treatment method is adopted, a prescription is screened in combination with pharmacological experiments, and after the medicines in the prescription are scientifically compatible, the traditional Chinese medicine composition has a good liver protection effect on chronic and acute hepatic failure patients clinically, has a good prevention and treatment effect on hepatic fibrosis in vivo, inhibits proliferation of activated hepatic stellate cells in vitro, has the efficacy of preventing liver cell injury, has a good anti-hepatic fibrosis effect, is a promising traditional Chinese medicine compound, and has a good market promotion value.

The invention discloses a pharmaceutical composition for treating Alpers-Huttenlocher syndrome, particularly drugs of the pharmaceutical composition and application of the drugs and pharmaceutical composition. The pharmaceutical composition for treating Alpers-Huttenlocher syndrome comprises sodium valproate and an anti-hepatic injury drug, wherein the anti-hepatic injury drug is selected from at least one of cyclosporin A, L-carnitine and N-acetylcysteine. The pharmaceutical composition can be used for treating Alpers-Huttenlocher syndrome, has favorable treatment effect, and is capable of obviously inhibit hepatocyte apoptosis, obviously relieving acute hepatic failure when the sodium valproate is used for treating patients with Alpers-Huttenlocher syndrome, and lowering the mortality of the patients.

The invention discloses a medicine composition for treating acute hepatic failure. Active ingredients of the medicine composition comprise Dioxasampsone A, and also comprise esculentoside D. Through being metered by weight, the ratio of the Dioxasampsone A to the esculentoside D is (1:1) to (20:1). A good effect is achieved on the treatment of acute hepatic failure when the weight ratio of the Dioxasampsone A to the esculentoside D is (8 to 11):1.

The invention relates to an establishing method of a macaca fascicularis acute liver failure model, comprising the step of injecting D-galactosamine to the external jugular vein of a macaca fascicularis. The acute hepatic failure of the macaca fascicularis is induced by an experimental mode through injecting D-galactosamine solution to the external jugular vein of the macaca fascicularis, and the established acute hepatic failure model can be well used for pre-clinical evaluation on safety and effectiveness of bioartificial liver systems.

Provided is a method for transdifferentiating fibroblasts into liver stem cells. The method reprograms fibroblasts into liver stem cells by using the three transcription factors, c-Jun, Foxa2, and Hnfl B. The obtained liver stem cells have the characteristics of self-renewal and bi-directional differentiation that are unique to liver stem cells. The induced liver stem cells prepared by the present application can be used as a cell source for the cell treatment for acute hepatic failure and end-stage liver diseases, and as seed cells for drug screening and tissue engineering liver preparation.

There is provided the compound N,N-bis-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically-acceptable salt and / or derivative thereof for use in the treatment or prevention of paracetamol toxicity. Such compounds have particular utility in the treatment or prevention of acute liver failure associated with paracetamol toxicity.

The invention relates to application of lactobacillus reuteri in preparation of a medicine for treating acute liver failure (AHF). In-depth research aiming at relieving liver and intestinal inflammation is conducted, and research objects are divided into a blank control group, a positive control group and a supplementary lactobacillus reuteri group. The result finds that the liver transaminase level, inflammatory factor IL-17 and intrahepatic inflammatory cell in the supplementary lactobacillus reuteri group are decreased, that is, the lactobacillus reuteri is supplemented every day preventively, so that liver and intestinal inflammation can be relieved when AHF occurs. In the context, it is desirable to alleviate liver and intestinal inflammation supplementing Lactobacillus reuteri preventively in healthy populations.

The invention relates to the liver full-immune cell characteristic spectrum research, and aims at provided a drawing method of acute hepatic failure mouse liver full-immune cell characteristic spectrum. The method comprises the following steps: mouse liver full-immune cells extraction; mass spectrum flow antibody marking; immune cell antibody dyeing; and mass spectrum flow cytometry. On the basisof guaranteeing the cell purity, the liver parenchyma cell can be removed as much as possible, thereby separating out the mouse liver full-immune cells in high yield. The yield of the separated mouseliver full-immune cell is higher than the yield of the grinding method, and the cell survival rate is greater than that of the traditional grinding method. According to immune cell features in the liver and lung, a kit is innovatively used for stabilizing the metal isotope and antibody; a mass spectrum flow channel is designed based on the channel minimum interference principle, the classificationand function of the liver full-immune cell can be comprehensively described, at most 43 markers can be detected at the same time, and the dynamic change of the mouse liver full-immune cell can be observed.